Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808558 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
A Phase 2 study of KRAS Gene Mutation, sponsored by David E Gerber.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT03808558 is a Phase 2 study of KRAS Gene Mutation that is active but no longer recruiting, run by David E Gerber. The registered enrollment target is 18 participants, below the 71-participant average among 3 other KRAS Gene Mutation trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03808558, a Phase 2 study of KRAS Gene Mutation, is active but no longer recruiting, sponsored by David E Gerber.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
Conditions Studied
Interventions
- DRUG TVB-2640
Study Locations (2)
Ohio
- University of Cincinnati - Cincinnati
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808558
The ClinicalTrials.gov registry entry for NCT03808558 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 3 other KRAS Gene Mutation trials with a reported enrollment target (75% lower). The listed sponsor is David E Gerber, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with KRAS Gene Mutation appearing as the primary indexed condition, and to 1 intervention - of which TVB-2640 is the first listed.
NCT03808558 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT03808558 about?
NCT03808558 is a clinical study titled "Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas". This is a prospective one-arm, two-stage phase 2 trial of TVB-2640 in KRAS mutant NSCLC patients. 13 patients will be treated with a minimum of 1 cycle of TVB-2640 therapy over 8 weeks.
What is the current status of trial NCT03808558?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-09-11. Estimated completion is 2026-12-01.
What conditions does trial NCT03808558 study?
This clinical trial studies the following conditions: KRAS Gene Mutation.
What interventions are being tested in trial NCT03808558?
The interventions under investigation include: TVB-2640 (DRUG).
Who is sponsoring clinical trial NCT03808558?
This trial is sponsored by David E Gerber, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03808558 being conducted?
This trial has 2 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for KRAS Gene Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.